Revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-Cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP).

被引：0
|
作者：
Sehn, LH
Chhanabhai, M
Fitzgerald, C
Gill, K
Hoskins, P
Klasa, R
Savage, K
Shenkier, T
Sutherland, J
Wilson, K
Gascoyne, RD
Connors, JM
机构：
[1] British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] British Columbia Canc Agcy, Div Pathol, Vancouver, BC V5Z 4E6, Canada
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
492
引用
收藏
页码：147A / 147A
页数：1
相关论文
共 50 条
  • [21] R-IPI in selecting patients with diffuse large B-cell lymphoma
    Stavrikj, S. Genadieva
    Stojanoski, Z.
    Veljanovska, A. Pivkova
    Balkanov, S. Krstevska
    Georgievski, B.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S543 - S543
  • [22] Re-Assessment of the Prognostic Value of International Prognostic Index (IPI) and Revised IPI (R-IPI) in patients with Diffuse Large B-Cell Lymphoma Treated with or without Rituximab in Chinese Populations: A Retrospective Multicenter Study by Shanghai Lymphoma Research Group
    Huang, Honghui
    Xiao, Fei
    Chen, Fangyuan
    Wang, Ting
    Li, Junmin
    Wang, Jianmin
    Cao, Junning
    Wang, Chun
    Zou, Shanhua
    BLOOD, 2011, 118 (21) : 1138 - 1138
  • [23] Publisher Correction: The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Xiaolei Wei
    Xiaoxiao Hao
    Lizhi Zhou
    Qi Wei
    Yuankun Zhang
    Weimin Huang
    Jialin Song
    Ru Feng
    Yongqiang Wei
    Scientific Reports, 9
  • [24] Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy
    Yang, Deok-Hwan
    Ahn, Jae Sook
    Kim, Yeo-Kyeoung
    Lee, Je-Jung
    Choi, Young Jin
    Shin, Ho Jin
    Chung, Joo-Seop
    Moon, Joon Ho
    Chae, Yee Soo
    Kim, Jong Gwang
    Sohn, Sang Kyun
    Kim, Hyeoung-Joon
    BLOOD, 2008, 112 (11) : 698 - 699
  • [25] Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution
    Queralt Salas, Maria
    Mercadal, Santiago
    Domingo Domenech, Eva
    Carla Oliveira, Ana
    Encuentra, Maite
    Climent, Fina
    Andrade Campos, Marcio
    Aguilera, Carmen
    Fernandez de Sevilla, Alberto
    Sureda, Anna
    Gonzalez-Barca, Eva
    LEUKEMIA & LYMPHOMA, 2019, : 575 - 581
  • [26] Both discordant and concordant bone marrow (BM) involvement predict for a poorer outcome independent of the IPI in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP
    Sehn, Laurie H.
    Chhanabhai, Mukesh
    Singh, Suman
    Saville, Wayne
    Matso, Dan
    Spinelli, John J.
    Connors, Joseph M.
    Gascoyne, Randy D.
    BLOOD, 2007, 110 (11) : 466A - 466A
  • [27] Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma
    Maurer, Matthew J.
    Jakobsen, Lasse H.
    Mwangi, Raphael
    Schmitz, Norbert
    Farooq, Umar
    Flowers, Cristopher R.
    de Nully Brown, Peter
    Thompson, Carrie A.
    Frederiksen, Henrik
    Cunningham, David
    Jorgensen, Judit
    Poeschel, Viola
    Nowakowski, Grzegorz
    Seymour, John F.
    Merli, Francesco
    Haioun, Corinne
    Ghesquieres, Herve
    Ziepert, Marita
    Tilly, Herve
    Salles, Gilles
    Shi, Qian
    El-Galaly, Tarec C.
    Habermann, Thomas M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : 599 - 605
  • [28] Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
    Liu, Zhiyu
    Xu-Monette, Zijun Y.
    Cao, Xin
    Visco, Carlo
    Tzankov, Alexander
    Montes-Moreno, Santiago
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ai, Weiyun
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Farnen, John P.
    Moller, Michael B.
    Winter, Jane N.
    Piris, Miguel A.
    Medeiros, L. Jeffrey
    Young, Ken H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S216 - S216
  • [29] The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Castillo, Jorge J.
    Beltran, Brady E.
    Song, Moo-Kon
    Ilic, Ivana
    Leppa, Sirpa
    Nurmi, Heidi
    Seki, Ritsuko
    Uccella, Silvia
    Li, Jun-Min
    Treaba, Diana O.
    Stachurski, Dariusz
    Butera, James N.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 413 - 417
  • [30] Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP.
    Batty, Nicolas
    Ghonimi, Elham
    Feng, Lei
    Fayad, Luis
    Younes, Anas
    Rodriguez, Maria Alma
    Romaguera, Jorge Enrique
    McLaughlin, Peter
    Samaniego, Felipe
    Kwak, Larry W.
    Hagemeister, Fredrick B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345